Tiotropium qd
Phase 3Small molecule
Boehringer IngelheimTiotropium qd is one of 110 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 3.
4
Indications
52
Total Trials
0
Active Trials
109
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Tiotropium qd
Boehringer IngelheimPhase 3
Singulair
AstraZenecaPreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Cinqair
TevaPreclinical
Celexa
AbbViePreclinical
Spiriva
Boehringer IngelheimPreclinical
Qvar
Chiesi Farmaceutici S.p.A.Preclinical
Formoterol Fumarate
AstraZenecaPreclinical
Symbicort
AstraZenecaPreclinical
Aciphex
Akero TherapeuticsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease19 trials
Show 16 more trials
Asthma13 trials
Show 10 more trials
Cystic Fibrosis3 trials
Salmeterol2 trials
11 more indications
Effectiveness2 trials
Efficacy and Safety1 trial
Optical Coherence Tomography1 trial
Treatment1 trial
Double-blind1 trial
Single Dose1 trial
Efficacy1 trial
Outcome1 trial
Maintenance Therapy1 trial
Unspecified2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tiotropium qd. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company